Medicare AdvantageReimbursementMedium impact
MA09.009w, Reimbursement for Radiopharmaceutical Agents for Professional Providers
Independence Blue Cross·Nuclear Medicine, Radiology, Oncology·Claims & Billing
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA09.009w establishes reimbursement guidelines for radiopharmaceutical agents billed by professional providers under Medicare Advantage plans, effective January 1, 2025. This recent policy (posted February 3, 2025) requires billing teams to review and align radiopharmaceutical claims submission practices with the new reimbursement framework to avoid claim denials.
Action Required
By February 28, 2025: Billing team must obtain and review the complete policy text from the provided URL to identify specific radiopharmaceutical HCPCS codes (likely J-codes) affected by this reimbursement policy. Once codes are identified, update billing system rules, claim submission procedures, and provider documentation requirements accordingly. Verify all radiopharmaceutical agent claims submitted since January 1, 2025 comply with the new reimbursement requirements. Contact the policy source (IBX) if clarification is needed on which codes, modifiers, or documentation are required for proper reimbursement. Failure to align with this policy may result in claim denials or payment delays for radiopharmaceutical services.